Your browser doesn't support javascript.
loading
Molecular mechanism of respiratory syncytial virus fusion inhibitors.
Battles, Michael B; Langedijk, Johannes P; Furmanova-Hollenstein, Polina; Chaiwatpongsakorn, Supranee; Costello, Heather M; Kwanten, Leen; Vranckx, Luc; Vink, Paul; Jaensch, Steffen; Jonckers, Tim H M; Koul, Anil; Arnoult, Eric; Peeples, Mark E; Roymans, Dirk; McLellan, Jason S.
Afiliação
  • Battles MB; Department of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
  • Langedijk JP; Janssen Infectious Diseases and Vaccines, Leiden, the Netherlands.
  • Furmanova-Hollenstein P; Janssen Infectious Diseases and Vaccines, Leiden, the Netherlands.
  • Chaiwatpongsakorn S; Center for Vaccines &Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Costello HM; Center for Vaccines &Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Kwanten L; Respiratory Infections Research, Janssen Infectious Diseases &Vaccines BVBA, Beerse, Belgium.
  • Vranckx L; Respiratory Infections Research, Janssen Infectious Diseases &Vaccines BVBA, Beerse, Belgium.
  • Vink P; Discovery Sciences, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Jaensch S; Discovery Sciences, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Jonckers TH; Medicinal Chemistry Department, Janssen Infectious Diseases &Vaccines BVBA, Beerse, Belgium.
  • Koul A; Respiratory Infections Research, Janssen Infectious Diseases &Vaccines BVBA, Beerse, Belgium.
  • Arnoult E; Computational Chemistry, Janssen R&D LLC, Spring House, Pennsylvania, USA.
  • Peeples ME; Center for Vaccines &Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Roymans D; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • McLellan JS; Respiratory Infections Research, Janssen Infectious Diseases &Vaccines BVBA, Beerse, Belgium.
Nat Chem Biol ; 12(2): 87-93, 2016 Feb.
Article em En | MEDLINE | ID: mdl-26641933
ABSTRACT
Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in young children and the elderly. Therapeutic small molecules have been developed that bind the RSV F glycoprotein and inhibit membrane fusion, yet their binding sites and molecular mechanisms of action remain largely unknown. Here we show that these inhibitors bind to a three-fold-symmetric pocket within the central cavity of the metastable prefusion conformation of RSV F. Inhibitor binding stabilizes this conformation by tethering two regions that must undergo a structural rearrangement to facilitate membrane fusion. Inhibitor-escape mutations occur in residues that directly contact the inhibitors or are involved in the conformational rearrangements required to accommodate inhibitor binding. Resistant viruses do not propagate as well as wild-type RSV in vitro, indicating a fitness cost for inhibitor escape. Collectively, these findings provide new insight into class I viral fusion proteins and should facilitate development of optimal RSV fusion inhibitors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Vírus Sinciciais Respiratórios / Modelos Moleculares / Proteínas Virais de Fusão Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Chem Biol Assunto da revista: BIOLOGIA / QUIMICA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Vírus Sinciciais Respiratórios / Modelos Moleculares / Proteínas Virais de Fusão Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Chem Biol Assunto da revista: BIOLOGIA / QUIMICA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos